Tag: AMGN

Advisors Capital Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 24.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,732 shares of the medical research company’s stock after purchasing an additional 534 shares during the period. Advisors Capital Management LLC’s holdings in Amgen were worth $661,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Tanglewood Legacy Advisors LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $26,000. Ruedi Wealth Management Inc. purchased a new stake in shares of Amgen during the fourth quarter worth about $27,000. GW&K Investment Management LLC lifted its holdings in Amgen by 200.0% in the fourth quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock worth $32,000 after buying an additional 80 shares during the period. AXS Investments LLC purchased a new stake in Amgen in the fourth quarter worth about $33,000. Finally, General Partner Inc. bought a new stake in shares of Amgen during the first quarter valued at approximately $32,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.7 %

Shares of Amgen stock opened at $230.41 on Thursday. The company has a market capitalization of $123.11 billion, a P/E ratio of 15.66, a P/E/G ratio of 1.91 and a beta of 0.63. The company has a debt-to-equity ratio of 11.36, a quick ratio of 2.79 and a current ratio of 3.14. The company has a fifty day moving average of $225.66 and a 200 day moving average of $235.47. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $296.67.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Friday, August 18th will be given a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a yield of 3.70%. Amgen’s dividend payout ratio (DPR) is currently 57.92%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AMGN. Barclays reduced their price target on shares of Amgen from $225.00 to $210.00 in a research report on Tuesday, July 11th. Mizuho lifted their target price on shares of Amgen from $208.00 to $214.00 in a research report on Wednesday, May 3rd. Piper Sandler cut their target price on shares of Amgen from $293.00 to $288.00 in a research report on Friday, April 28th. Jefferies Financial Group cut their target price on shares of Amgen from $325.00 to $275.00 in a research report on Friday, July 7th. Finally, Credit Suisse Group cut their target price on shares of Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $249.12.

Get Our Latest Stock Analysis on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.

Kestra Advisory Services LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 14.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 55,910 shares of the medical research company’s stock after selling 9,718 shares during the period. Kestra Advisory Services LLC’s holdings in Amgen were worth $14,684,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. EdgeRock Capital LLC acquired a new position in Amgen during the third quarter worth about $25,000. Leelyn Smith LLC raised its position in Amgen by 80.3% during the third quarter. Leelyn Smith LLC now owns 110 shares of the medical research company’s stock worth $25,000 after acquiring an additional 49 shares during the last quarter. Glassy Mountain Advisors Inc. acquired a new position in Amgen during the fourth quarter worth about $26,000. Legacy Bridge LLC raised its position in Amgen by 930.0% during the fourth quarter. Legacy Bridge LLC now owns 103 shares of the medical research company’s stock worth $27,000 after acquiring an additional 93 shares during the last quarter. Finally, RFP Financial Group LLC acquired a new position in Amgen during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 75.53% of the company’s stock.

Amgen Price Performance

AMGN opened at $250.00 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.41 and a debt-to-equity ratio of 10.20. Amgen Inc. has a 52-week low of $223.30 and a 52-week high of $296.67. The company has a 50 day moving average of $239.01 and a two-hundred day moving average of $255.87. The company has a market cap of $133.56 billion, a P/E ratio of 20.64, a P/E/G ratio of 2.03 and a beta of 0.64.

Amgen (NASDAQ:AMGN – Get Rating) last released its quarterly earnings data on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.05. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The company had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the firm earned $4.36 earnings per share. Amgen’s revenue for the quarter was down .1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post 17.73 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be paid a dividend of $2.13 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 annualized dividend and a yield of 3.41%. Amgen’s dividend payout ratio is currently 70.36%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. SVB Securities cut their target price on shares of Amgen from $282.00 to $267.00 in a research report on Thursday, February 2nd. Truist Financial cut their price objective on shares of Amgen from $280.00 to $260.00 and set a “buy” rating for the company in a research report on Monday, February 13th. Argus cut their price objective on shares of Amgen from $300.00 to $270.00 in a research report on Monday, February 6th. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and cut their price objective for the company from $275.00 to $265.00 in a research report on Monday, March 13th. Finally, Cowen cut their price objective on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $251.25.

Amgen Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Get Rating).

Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.

Plimoth Trust Co. LLC lowered its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,251 shares of the medical research company’s stock after selling 165 shares during the quarter. Plimoth Trust Co. LLC’s holdings in Amgen were worth $1,117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. EdgeRock Capital LLC acquired a new stake in shares of Amgen in the third quarter valued at $25,000. Leelyn Smith LLC boosted its position in shares of Amgen by 80.3% in the 3rd quarter. Leelyn Smith LLC now owns 110 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 49 shares during the period. Capital Wealth Alliance LLC purchased a new position in shares of Amgen in the second quarter worth approximately $26,000. Glassy Mountain Advisors Inc. acquired a new stake in Amgen during the 4th quarter valued at $26,000. Finally, Coston McIsaac & Partners purchased a new stake in Amgen in the 2nd quarter worth about $27,000. Institutional investors own 75.53% of the company’s stock.

Amgen Trading Up 0.7 %

Shares of Amgen stock opened at $239.64 on Monday. The company has a debt-to-equity ratio of 10.20, a current ratio of 1.41 and a quick ratio of 1.10. The business has a fifty day simple moving average of $242.09 and a two-hundred day simple moving average of $254.57. Amgen Inc. has a 1 year low of $223.30 and a 1 year high of $296.67. The company has a market capitalization of $127.96 billion, a price-to-earnings ratio of 19.66, a P/E/G ratio of 1.92 and a beta of 0.65.

Amgen (NASDAQ:AMGN – Get Rating) last announced its earnings results on Tuesday, February 7th. The medical research company reported $4.09 EPS for the quarter, topping the consensus estimate of $4.04 by $0.05. The business had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. Amgen’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.36 EPS. Research analysts forecast that Amgen Inc. will post 17.72 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Thursday, May 18th will be issued a dividend of $2.13 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 annualized dividend and a yield of 3.56%. Amgen’s payout ratio is currently 70.36%.

Wall Street Analyst Weigh In

A number of research analysts have commented on AMGN shares. Credit Suisse Group lowered their target price on Amgen from $240.00 to $220.00 and set an “underperform” rating on the stock in a research note on Wednesday, February 1st. BMO Capital Markets reduced their price objective on Amgen from $276.00 to $253.00 and set a “market perform” rating for the company in a research report on Wednesday, February 1st. Piper Sandler reduced their price objective on Amgen from $299.00 to $293.00 and set an “overweight” rating for the company in a research report on Thursday, January 19th. SVB Leerink lowered their target price on shares of Amgen from $282.00 to $267.00 and set a “market perform” rating on the stock in a research note on Thursday, February 2nd. Finally, Barclays dropped their price objective on Amgen from $240.00 to $230.00 and set an “underweight” rating for the company in a research note on Wednesday, February 1st. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $251.44.

Amgen Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Read More

Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.